Shelly M P, Dixon J S, Park G R
Intensive Care Unit, Addenbrooke's Hospital, Cambridge.
Br J Clin Pharmacol. 1989 May;27(5):629-33. doi: 10.1111/j.1365-2125.1989.tb03428.x.
Seven patients with chronic liver disease received a 10 mg intravenous bolus dose of midazolam immediately following orthotopic liver transplantation. Plasma samples were analysed for midazolam and alpha-hydroxymidazolam by gas chromatography with electron capture detection. Data from three patients could not be evaluated. In the remaining four patients the pharmacokinetics of midazolam were essentially normal but the plasma concentrations of alpha-hydroxy-midazolam were higher than those found in healthy subjects. All patients required further sedation between 0.5 and 5 h later indicating that the duration of action of midazolam was not prolonged. These results suggest that following liver transplantation, patients have considerable drug metabolising capacity either in the liver or at extrahepatic sites.
七名慢性肝病患者在原位肝移植后立即接受了10毫克咪达唑仑静脉推注剂量。通过带有电子捕获检测的气相色谱法分析血浆样本中的咪达唑仑和α-羟基咪达唑仑。三名患者的数据无法评估。在其余四名患者中，咪达唑仑的药代动力学基本正常，但α-羟基咪达唑仑的血浆浓度高于健康受试者。所有患者在0.5至5小时后都需要进一步镇静，这表明咪达唑仑的作用持续时间没有延长。这些结果表明，肝移植后，患者在肝脏或肝外部位具有相当大的药物代谢能力。
